New pill targets tough cancers: first human trial begins
NCT ID NCT05142592
Summary
This early-stage trial is testing a new oral medication called IPG7236 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine safe dosage levels and then expand to specific cancer types including kidney, breast, head/neck, and melanoma. The study aims to understand how the drug works in the body and whether it shows signs of controlling tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGAustin, Texas, 12221, United States
Contact
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97222, United States
Contact
-
Shandong Cancer Hospital
RECRUITINGJinan, Shangdong, China
Contact
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact
-
Shanghai General Hospital
ACTIVE_NOT_RECRUITINGShanghai, China
-
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITINGShanghai, China
Contact
-
The First Affiliated Hospital Nanchang Univeristy
RECRUITINGNanchang, Jiangxi, China
Contact
Conditions
Explore the condition pages connected to this study.